Literature DB >> 8150229

Nerve ischaemia in diabetic rats: time-course of development, effect of insulin treatment plus comparison of streptozotocin and BB models.

E J Stevens1, A L Carrington, D R Tomlinson.   

Abstract

This study sought to determine the time-course of development of reduced nerve laser Doppler flux in experimental diabetes and the effect on this anomaly of insulin treatment. In addition, we aimed to compare nerve laser Doppler flux in streptozotocin- and genetically-diabetic BB rat models. Sciatic nerve laser Doppler flux in diabetic rats was variable during the 2 days following streptozotocin injection; from day 4, when the measurement was 80% of control, fluxes fell steadily and formed a plateau at 40% of control values after 4 weeks of diabetes. In a second study, using rats with 4-week streptozotocin-diabetes, sciatic nerve laser Doppler flux was reduced to 44% of the value measured in control rats. Treatment of a parallel group of diabetic rats with insulin, by sustained release implants, prevented this ischaemia, so that nerve laser Doppler flux was 91% of controls. Nerve Doppler flux in BB rats with 6-week genetic diabetes was 57% of a control (non-diabetic) BB group. There were no differences in mean arterial pressures between control and diabetic rats in any of the studies. Heart rates of control and insulin-treated diabetic animals were higher than those of the untreated diabetic group; in the other studies heart rates of diabetic animals were numerically lower than controls, but not significantly so. These observations suggest that sciatic nerves of rats with short-term diabetes, whether induced with streptozotocin or of genetic origin, are markedly ischaemic and that this ischaemia in streptozotocin-diabetes is evident within a week of diabetes onset, forms a plateau after 4 weeks and is maintained for at least 2 months.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8150229     DOI: 10.1007/bf00428776

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  35 in total

Review 1.  Aldose reductase inhibitors and diabetic complications.

Authors:  D R Tomlinson; G B Willars; A L Carrington
Journal:  Pharmacol Ther       Date:  1992       Impact factor: 12.310

2.  Sural nerve oxygen tension in diabetes.

Authors:  P G Newrick; A J Wilson; J Jakubowski; A J Boulton; J D Ward
Journal:  Br Med J (Clin Res Ed)       Date:  1986-10-25

3.  Comparison between spontaneously beating atria from control and streptozocin-diabetic rats.

Authors:  J M Foy; P D Lucas
Journal:  J Pharm Pharmacol       Date:  1978-09       Impact factor: 3.765

4.  Dynamic peripheral nerve metabolic and vascular responses to exsanguination.

Authors:  M Takeuchi; P A Low
Journal:  Am J Physiol       Date:  1987-10

5.  Blood pressure in streptozotocin-treated Brattleboro and Long-Evans rats.

Authors:  K C Tomlinson; S M Gardiner; T Bennett
Journal:  Am J Physiol       Date:  1990-04

6.  Nerve function in experimental diabetes in rats: effects of electrical stimulation.

Authors:  N E Cameron; M A Cotter; S Robertson; E K Maxfield
Journal:  Am J Physiol       Date:  1993-02

7.  Aminoguanidine, a novel inhibitor of nitric oxide formation, prevents diabetic vascular dysfunction.

Authors:  J A Corbett; R G Tilton; K Chang; K S Hasan; Y Ido; J L Wang; M A Sweetland; J R Lancaster; J R Williamson; M L McDaniel
Journal:  Diabetes       Date:  1992-04       Impact factor: 9.461

8.  Essential fatty acid treatment prevents nerve ischaemia and associated conduction anomalies in rats with experimental diabetes mellitus.

Authors:  E J Stevens; M J Lockett; A L Carrington; D R Tomlinson
Journal:  Diabetologia       Date:  1993-05       Impact factor: 10.122

9.  The spontaneously diabetic BB Wistar rat. Morphologic and physiologic studies of peripheral nerve.

Authors:  J R Mendell; Z Sahenk; J R Warmolts; J K Marshall; P Thibert
Journal:  J Neurol Sci       Date:  1981-10       Impact factor: 3.181

10.  The effects of dietary treatment with essential fatty acids on sciatic nerve conduction and activity of the Na+/K+ pump in streptozotocin-diabetic rats.

Authors:  M J Lockett; D R Tomlinson
Journal:  Br J Pharmacol       Date:  1992-02       Impact factor: 8.739

View more
  12 in total

1.  Reversal of experimental diabetic neuropathy by VEGF gene transfer.

Authors:  P Schratzberger; D H Walter; K Rittig; F H Bahlmann; R Pola; C Curry; M Silver; J G Krainin; D H Weinberg; A H Ropper; J M Isner
Journal:  J Clin Invest       Date:  2001-05       Impact factor: 14.808

2.  Can VEGF reverse diabetic neuropathy in human subjects?

Authors:  A Veves; G L King
Journal:  J Clin Invest       Date:  2001-05       Impact factor: 14.808

3.  Acetylcholine-induced arteriolar dilation is reduced in streptozotocin-induced diabetic rats with motor nerve dysfunction.

Authors:  K Terata; L J Coppey; E P Davidson; J A Dunlap; D D Gutterman; M A Yorek
Journal:  Br J Pharmacol       Date:  1999-10       Impact factor: 8.739

Review 4.  Vascular factors in diabetic neuropathy.

Authors:  S Tesfaye; R Malik; J D Ward
Journal:  Diabetologia       Date:  1994-09       Impact factor: 10.122

5.  Effects of anti-oxidant treatment on sciatic nerve dysfunction in streptozotocin-diabetic rats; comparison with essential fatty acids.

Authors:  C Karasu; M Dewhurst; E J Stevens; D R Tomlinson
Journal:  Diabetologia       Date:  1995-02       Impact factor: 10.122

6.  The effects of aldose reductase inhibition with ponalrestat on changes in vascular function in streptozotocin diabetic rats.

Authors:  D J Otter; R Chess-Williams
Journal:  Br J Pharmacol       Date:  1994-10       Impact factor: 8.739

7.  Alpha-lipoic Acid and diabetic neuropathy.

Authors:  Natalia Vallianou; Angelos Evangelopoulos; Pavlos Koutalas
Journal:  Rev Diabet Stud       Date:  2009-12-30

8.  Neuroprotective effects of carvedilol in diabetic rats: prevention of defective peripheral nerve perfusion and conduction velocity.

Authors:  M A Cotter; N E Cameron
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1995-06       Impact factor: 3.000

9.  Effects of endothelin receptor antagonism with bosentan on peripheral nerve function in experimental diabetes.

Authors:  E J Stevens; D R Tomlinson
Journal:  Br J Pharmacol       Date:  1995-05       Impact factor: 8.739

10.  Deficient nitric oxide responsible for reduced nerve blood flow in diabetic rats: effects of L-NAME, L-arginine, sodium nitroprusside and evening primrose oil.

Authors:  N Omawari; M Dewhurst; P Vo; S Mahmood; E Stevens; D R Tomlinson
Journal:  Br J Pharmacol       Date:  1996-05       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.